Evidence map›Paper›PMID 31590967›Full record

Trial reportMayo Clinic proceedings2019

BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Saul M Genuth, Helen Vlachos, Maria Mori Brooks, John P Bantle, Bernard R Chaitman, Jennifer Green, Sheryl F Kelsey, Spencer B King, Robert McBane, Edward Y Sako and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Mayo Clinic proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00006305 (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00006305 phase3completednot on this map

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes

TypeinterventionalSponsorUniversity of PittsburghRan2000 to 2009Enrolled2,368ConditionsCoronary Disease, Cardiovascular Diseases, Heart Diseases, Insulin ResistanceArmsAngioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Coronary Artery Bypass, Biguanides, thiazolidinediones, Insulin, sulfonylurea, ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Saul M GenuthDivision of Clinical and Molecular Endocrinology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Helen VlachosEpidemiology Data Center, University of Pittsburgh, PA.
Maria Mori BrooksEpidemiology Data Center, University of Pittsburgh, PA. Electronic address: mbrooks@pitt.edu.
John P BantleDepartment of Medicine, University of Minnesota, Minneapolis; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
Bernard R ChaitmanDivision of Cardiology, Department of Medicine, St. Louis University, MO.
Jennifer GreenDivision of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC.
Sheryl F KelseyEpidemiology Data Center, University of Pittsburgh, PA.
Spencer B KingEmory University School of Medicine, Atlanta, GA.
Robert McBaneMayo Clinic, Rochester, MN.
Edward Y SakoDepartment of Cardiothoracic Surgery, University of Texas Health Science Center at San Antonio.
David J SchneiderDepartment of Medicine, University of Vermont Medical Center, Burlington.
Michael SteffesDepartment of Medicine, University of Minnesota, Minneapolis; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
Robert L FryeMayo Clinic, Rochester, MN.
BARI 2D Study Group

Funding

BARI II:Foreign RecruitmentU01HL061744 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2000 to 2005
$41.1M
BARI II - FIBRINOLYSIS AND COAGULATION COREU01HL063804 · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · 2000 to 2005
$3.3M
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2U01HL061748 · STANFORD UNIVERSITY · 2000 to 2005
$2.1M
BARI II GRANT PROPOSAL FOR ECG CORE LABORATORYU01HL061746 · SAINT LOUIS UNIVERSITY · 2000 to 2005
$1.2M
NHLBI NIH HHS R21 HL121495NHLBI NIH HHS U01 HL061744NHLBI NIH HHS U01 HL061746NHLBI NIH HHS U01 HL061748NHLBI NIH HHS U01 HL063804
6 · The paper itself

Abstract

objectiveTo reanalyze the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial using a new composite cardiovascular disease (CVD) outcome to determine how best to treat patients with type 2 diabetes mellitus and stable coronary artery disease. PATIENTS AND

methodsFrom January 1, 2001, to November 30, 2008, 2368 patients with type 2 diabetes mellitus and angiographically proven coronary artery disease were randomly assigned to insulin-sensitizing (IS) or insulin-providing (IP) therapy and simultaneously to coronary revascularization (REV) or no or delayed REV (intensive medical therapy [MED]), with all patients receiving intensive medical treatment. The outcome of this analysis was a composite of 8 CVD events.

resultsFour-year Kaplan-Meier rates for the composite CVD outcome were 35.8% (95% CI, 33.1%-38.5%) with IS therapy and 41.6% (95% CI, 38.7%-44.5%) with IP therapy (P=.004). Much of this difference was associated with lower in-trial levels of fibrinogen, C-reactive protein, and hemoglobin A

conclusionIn the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, the IS treatment strategy and the REV treatment strategy each reduces cardiovascular events. The combination of IS drugs and CABG results in the lowest risk of subsequent CVD events.

trial registrationclinicaltrials.gov Identifier: NCT00006305.

Indexed as

Coronary Artery BypassAngina, StableCoronary Artery DiseaseDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInsulinInsulin ResistanceMaleMiddle AgedTreatment OutcomeHypoglycemic AgentsInsulin

Identifiers

PMID31590967
PMCPMC6832788

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.